INSM241220C25000
- 50.15
- 0.000.00%
Insmed Newsroom
Insmed To Present at December 2024 Investor Conferences
Insmed Insiders Sold US$3.8m Of Shares Suggesting Hesitancy
Insmed Is Maintained at Overweight by JP Morgan
Demystifying Insmed: Insights From 7 Analyst Reviews
Insmed Analyst Ratings
J.P. Morgan Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $83
Optimistic Revenue Forecast for Insmed Following Brensocatib's Launch and Strategic Developments
Express News | Insmed Inc : JP Morgan Raises Target Price to $83 From $74
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Insmed's Strategic Growth and Market Potential Drive Buy Recommendation
Goldman's Hedge Fund VIP List: AMZN, VST, CRM, BABA, and More
Top Gap Ups and Downs on Tuesday: SMCI, WMT, BBY and More
Express News | Insmed Inc - No Termination Penalties for Terminating Agreement
Express News | Insmed Inc - Terminates Sales Agreement With Leerink Partners LLC Effective Immediately
Insmed's Options: A Look at What the Big Money Is Thinking
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
Unusual Options Activity: INSM, BGC and Others Attract Market Bets, INSM V/OI Ratio Reaches 176.5
Express News | Insmed Inc : Mizuho Cuts Target Price to $88 From $92
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Express News | Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)